The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients<subtitle>A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4</subtitle><alt-title>Antiretroviral Drugs, Risk of MI, and HIV</alt-title>
Abstract
BACKGROUND: The role of exposure to specific antiretroviral drugs on risk of myocardial infarction in human immunodeficiency virus (HIV)-infected patients is debated in the literature. METHODS: To assess whether we confirmed the association between exposure to abacavir and risk of myocardial infarction (MI) and to estimate the impact of exposure to other nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and non-NRTIs on risk of MI, we conducted a case-control study nested within the French Hospital Database on HIV. Cases (n = 289) were patients who, between January 2000 and December 2006, had a prospectively recorded first definite or probable MI. Up to 5 controls (n = 884), matched for age, sex, and clinical center, were selected at random with replacement among patients with no history of MI already enrolled in the database when MI was diagnosed in the corresponding case. Conditional logistic regression models were used to adjust for potential confounders. RESULTS: Short-term/recent exposure to abacavir was associated with an increased risk of MI in the overall sample (odds ratios [ORs], 2.01; 95% confidence interval [CI], 1.11-3.64) but not in the subset of matched cases and controls (81%) who did not use cocaine or intravenous drugs (1.27; 0.64-2.49). Cumulative exposure to all PIs except saquinavir was associated with an increased risk of MI significant for amprenavir/fosamprenavir with or without ritonavir (OR, 1.53; 95% CI, 1.21-1.94 per year) and lopinavir with ritonavir (1.33; 1.09-1.61 per year). Exposure to all non-NRTIs was not associated with risk of MI. CONCLUSION: The risk of MI was increased by cumulative exposure to all the studied PIs except saquinavir and particularly to amprenavir/fosamprenavir with or without ritonavir and lopinavir with ritonavir, whereas the association with abacavir cannot be considered causal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence-Based Medicine: How to Practice and Teach EBM
Sackett, D. L. (2000) · Cited by 5,950
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Evidence-based medicine : how to practice and teach EBM
Straus, S. E. (2005) · Cited by 1,367
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study
Anand, S. S., Islam, S., Rosengren, A., Franzosi, M. G., Steyn, K., Yusufali, A. H., Keltai, M., Diaz, R., Rangarajan, S., & Yusuf, S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn018 · Cited by 909
Luepker, R. V., Apple, F. S., Christenson, R. H., Crow, R. S., Fortmann, S. P., Goff, D., Goldberg, R. J., Hand, M. M., Jaffe, A. S., Julian, D. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000100560.46946.ea · Cited by 810
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 648
Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., & Costagliola, D. (2003) · AIDS · doi:10.1097/00002030-200311210-00010 · Cited by 564
Severe premature coronary artery disease with protease inhibitors
Henry, K., Melroe, H., Huebsch, J., Hermundson, J., Levine, C., Swensen, L., & Daley, J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79053-x · Cited by 513
McCord, J., Jneid, H., Hollander, J. E., de Lemos, J. A., Cercek, B., Hsue, P., Gibler, W. B., Ohman, E. M., Drew, B., Philippides, G., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188950 · Cited by 429
van Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., Wood, R., Bloch, M., Katlama, C., Kastelein, J. J. P., et al. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010019 · Cited by 276
Vascular complications associated with use of HIV protease inhibitors
Gallet, B., Pulik, M., Genet, P., Chedin, P., & Hiltgen, M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78643-8 · Cited by 253
Martin, A., Bloch, M., Amin, J., Baker, D., Cooper, D. A., Emery, S., & Carr, A. (2009) · Clinical Infectious Diseases · doi:10.1086/644769 · Cited by 222
Smith, K. Y., Patel, P., Fine, D., Bellos, N., Sloan, L., Lackey, P., Kumar, P. N., Sutherland-Phillips, D. H., Vavro, C., Yau, L., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832cbcc2 · Cited by 217
Brothers, C. H., Hernandez, J. E., Cutrell, A. G., Curtis, L., Ait-Khaled, M., Bowlin, S. J., Hughes, S. H., Yeo, J. M., & Lapierre, D. H. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819ff0e6 · Cited by 182
Hsue, P. Y., Hunt, P. W., Wu, Y., Schnell, A., Ho, J. E., Hatano, H., Xie, Y., Martin, J. N., Ganz, P., & Deeks, S. G. (2009) · AIDS · doi:10.1097/qad.0b013e32832e7140 · Cited by 167
Obel, N., Farkas, D. K., Kronborg, G., Larsen, C. S., Pedersen, G., Riis, A. H., Pedersen, C. D., Gerstoft, J., & Sørensen, H. T. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00751.x · Cited by 144
Walmsley, S. L., Avihingsanon, A., Slim, J., Ward, D. J., Ruxrungtham, K., Brunetta, J., Bredeek, U. F., Jayaweera, D. T., Guittari, C. J., Larson, P., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318198a815 · Cited by 116
A new era of antiretroviral drug toxicity
Calmy, A., Hirschel, B. J., Cooper, D. A., & Carr, A. D. (2008) · Antiviral Therapy · doi:10.1177/135965350901400203 · Cited by 67
Mercier, S., Gueye, N. F. N., Cournil, A., Fontbonne, A., Copin, N., Ndiaye, I., Dupuy, A., Cames, C., Sow, P. S., Ndoye, I., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819c16f4 · Cited by 65
Kristoffersen, U. S., Kofoed, K. F., Kronborg, G., Benfield, T., Kjær, A., & Lebech, A. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00733.x · Cited by 34
Guiguet, M., Mary‐Krause, M., Ename, B., Costagliola, D. G., & Grabar, S. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1581 · Cited by 3
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Hasse, B., Ledergerber, B., Furrer, H., Battegay, M., Hirschel, B., Cavassini, M., Bertisch, B., Bernasconi, E., Weber, R., & Study, T. S. H. C. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir626 · Cited by 608
Tenorio, A. R., Zheng, Y., Bosch, R. J., Krishnan, S., Rodriguez, B., Hunt, P. W., Plants, J., Seth, A., Wilson, C. C., Deeks, S. G., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu254 · Cited by 546
Metadata
- Authors
- Lang, S.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2010-07-26
- Volume
- 170
- Issue
- 14
- Pages
- 1228
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1606409921
- Cited by
- 306
- References
- 24
- FWCI
- 36.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.